Frequency Therapeutics

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The firm's progenitor cell activation approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

FedEx

Guess?

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys: Guess, FedEx And More

Applied Therapeutics Inc

Green Brick Partners

Kelly Services

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

4 Stocks to Make the Most of New Analyst Coverage

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

Frequency Therapeutics Announces $42 Million Private Placement

Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising

Aprea Therapeutics

Vir Biotechnology

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

These 4 Biotechs Have Selling Pressure on the Horizon

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Are These 3 Recent Biotech IPOs A Good Deal For Investors?

Frequency Therapeutics (NASDAQ: FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.

Frequency Therapeutics Opens Below IPO Price

News for Frequency Therapeutics Stock (FREQ)